CN114588233A - Composition for treating acute gout - Google Patents
Composition for treating acute gout Download PDFInfo
- Publication number
- CN114588233A CN114588233A CN202110716052.9A CN202110716052A CN114588233A CN 114588233 A CN114588233 A CN 114588233A CN 202110716052 A CN202110716052 A CN 202110716052A CN 114588233 A CN114588233 A CN 114588233A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- gypsum
- rhizoma anemarrhenae
- lily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 201000005569 Gout Diseases 0.000 title claims abstract description 47
- 230000001154 acute effect Effects 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 36
- 241000234435 Lilium Species 0.000 claims abstract description 24
- 239000010440 gypsum Substances 0.000 claims abstract description 24
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 24
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 19
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 18
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 18
- 241000237502 Ostreidae Species 0.000 claims abstract description 18
- 235000020636 oyster Nutrition 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 4
- 239000006184 cosolvent Substances 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- -1 sucrose ester Chemical class 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 4
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 4
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 4
- 229940083466 soybean lecithin Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000000857 drug effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 description 19
- 210000002784 stomach Anatomy 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 208000006820 Arthralgia Diseases 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 206010018634 Gouty Arthritis Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 210000000544 articulatio talocruralis Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 3
- 241000132012 Atractylodes Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 208000030175 lameness Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 229950000193 oteracil Drugs 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000605445 Anemarrhena asphodeloides Species 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010020601 Hyperchlorhydria Diseases 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 240000009022 Smilax rotundifolia Species 0.000 description 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 241000218158 Clematis Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 241000380450 Danaus melanippus Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 240000003915 Lophatherum gracile Species 0.000 description 1
- 241000729196 Lycopus lucidus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 244000148137 Patrinia villosa Species 0.000 description 1
- 235000019109 Patrinia villosa Nutrition 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 244000171085 Polyporus umbellatus Species 0.000 description 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 1
- 241000270273 Ptyas dhumnades Species 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 241000205578 Thalictrum Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine treatment, and particularly relates to a composition for treating acute gout. The composition comprises the following raw materials in parts by mass: 1-10 parts of gypsum, 1-10 parts of rhizoma anemarrhenae, 5-10 parts of lily, 1-10 parts of cassia twig, 1-5 parts of liquorice, 1-5 parts of calcined oyster and 1-10 parts of coix seed. The preparation method comprises decocting Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen in water, filtering, concentrating, and drying. The invention has simple prescription, simple preparation method and definite drug effect, and has no toxic or side effect when being taken for a long time to treat gout.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicine treatment, and particularly relates to a composition for treating acute gout.
Background
Gout is a clinical syndrome of sodium urate or uric acid crystals deposited in joints and surrounding joint capsules, bursa synovialis, cartilage and bone, and belongs to the category of metabolic diseases. The clinical manifestations are hyperuricemia, acute gouty arthritis, tophus deposition, tophaceous chronic arthritis and joint deformity. Gout is a common disease and frequently encountered disease in clinic, and is common in men, and the onset age is more after 40 years of age, and the onset age tends to be younger along with the improvement of living standard and the change of dietary structure of people. Acute gouty arthritis is the most basic type of gout, is the largest in proportion among patients with gout at home visit, is easy to cause disability and teratogenesis if not actively prevented and treated, and influences joint functions, so that people pay more attention to gouty arthritis, and review risk factors and prevention strategies of the disease, so that gout treatment and control become hot spots of global medical field attention.
Acute gouty arthritis is the most common first symptom of gout, is clinically manifested by red, hot, swollen, painful joints and surrounding tissues and limited functions, and the condition of the disease is easy to repeat, thereby bringing great pain to patients. At present, no curative medicine for acute gouty arthritis exists, colchicine, non-steroidal anti-inflammatory drugs, glucocorticoid and the like are mostly adopted in western medicine to relieve symptoms, but the side effects of the medicine are obvious, and the damage to the liver, the kidney and the digestive tract of a human body is obvious after the medicine is taken for a long time. At present, western medicine still can not make breakthrough progress on the treatment of gout, and traditional Chinese medicine takes dialectical treatment as guidance, treats the disease and seeks the root, takes strengthening body resistance and eliminating evil, and treats both principal and secondary aspects of disease as principles, can not only effectively control the clinical symptoms in the acute stage and slow down the occurrence time limit of complications, but also has less adverse reaction compared with western medicine, low price, easy acceptance of patients and capacity of insisting on treatment.
Gout belongs to the categories of arthralgia syndrome, pyretic arthralgia, white tiger's almanac, wandering wind and the like in the traditional Chinese medicine. The Huangdi's classic on medicine considers that arthralgia-syndrome will cause the related diseases of the five internal organs, which are recorded as follows: so bone impediment is not existed, the disease is caused by the evil again and is internally generated in the kidney; … … the arthralgia will be caused by the invasion of pathogenic factors and will be retained in the lung. "this means that ancient physicians in our country have long recognized that arthralgia will affect important organs such as heart vessels, kidneys and the like, which is consistent with the theory of modern medicine. The record of "jin Kui Yao L ü e": the deficient pulse is deficient and superficial, the weak pulse is deficient, … … is profuse and astringent, short breath and spontaneous sweating, pain in the course of the festival, not yielding, which are all caused by drinking sweat and wind. … … Gui Zhi Shao Zhi mu Zhi Tang. The gout is caused by deficiency of qi and blood, exogenous wind-damp heat pathogen and overeating sorghum with thick taste, so that the joint is painful, red and swollen, and the activity is limited. Zhu Dan xi creates the name of gout, which is recorded in Dan xi Xin Fa: "gout sufferer … … with red, swollen and hot pain. "" general pain … … is like a tiger bite. So it is also called Baihu Xiaoaifeng. "
The basic pathogenesis of gout is that spleen and stomach are weak, the spleen and stomach are bitter, the taste of the paste is strong, the spleen and stomach are disordered in transportation and transformation, the ascending and descending are abnormal, water and drink can not be distributed, the water and drink are gathered in the middle-jiao to become damp, the damp and heat are accumulated for a long time, and the dampness and the heat flow into joints of four limbs, so that the qi and the blood of the joints are not smooth to move, and the gout is developed. The understanding of the pathogenesis of gout is different among doctors. The inventor considers that the physique of gout patients is generally characterized by strong stomach qi and vigorous yangming channel qi, and high-purine diet causes the yangming channel qi to be vigorous to generate external heat and the Taiyin channel qi to be deficient to generate internal cold, and finally the gout is caused. For interior syndrome of excess heat, it is indicated for arthralgia of meridians besides clearing yang and clearing excess heat.
The Chinese invention patent CN101732623B discloses a medicine for treating acute gouty arthritis and a preparation method thereof, wherein the medicine comprises the following components in parts by weight: 4-7 parts of rhizoma atractylodis, 6-9 parts of dandelion, 5-8 parts of honeysuckle, 6-9 parts of gypsum, 4-7 parts of ginseng, 5-8 parts of pawpaw, 4-7 parts of Chinese yam, 6-9 parts of semen coicis, 6-9 parts of talc, 3-6 parts of lophatherum gracile, 3-6 parts of rhizoma anemarrhenae, 2-4 parts of polyporus umbellatus, 6-9 parts of glabrous greenbrier rhizome, 5-8 parts of hiraute shiny bugleweed herb, 0.3-0.6 part of roasted nux vomica and 6-9 parts of dahurian patrinia herb, and the medicines are used together for synergism and complementation, so that the effects of excreting dampness and discharging turbidity, clearing heat and detoxifying, removing blood stasis and relieving pain are achieved, the interconversion of damp and heat stasis toxin is prevented, and the pathological link is terminated. However, the invention has more medicinal ingredients and more complex prescription, and the action effect needs to be further improved.
The Chinese invention patent CN104069391B discloses a Chinese medicinal composition for treating gout and hyperuricemia and a preparation method thereof, and the Chinese medicinal composition comprises the following medicaments: 20-40 g of ash bark, 5-20 g of dark plum fruit, 5-25 g of honeysuckle stem, 5-25 g of glabrous greenbrier rhizome, 5-20 g of desmodium, 5-20 g of plantain herb, 5-20 g of giant knotweed rhizome, 5-20 g of raw coix seed, 5-20 g of largehead atractylodes rhizome, 5-25 g of yam, 5-25 g of clematis root, 5-20 g of grape seed, 5-20 g of meadowrue SU, 520 g of lily bulb, 5-25 g of Chinese sage herb and 10-30 g of raw oyster shell. The traditional Chinese medicine composition consists of 16 medicines, has the same complex medicine taste and weak clinical adaptability.
The Chinese invention patent CN107929598A discloses a traditional Chinese medicine composition for treating gout and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10-20 parts of bighead atractylodes rhizome, 10-15 parts of poria cocos, 10-20 parts of semen coicis, 10-15 parts of rhizoma atractylodis, 15-30 parts of gypsum, 10-15 parts of cassia twig, 10-20 parts of rhizoma anemarrhenae, 10-15 parts of cortex moutan, 10-15 parts of cortex phellodendri, 10-30 parts of radix salviae miltiorrhizae, 15-20 parts of caulis spatholobi, 10-15 parts of pangolin, 10-20 parts of herba lycopi, 2 centipedes, 15-20 parts of zaocys dhumnade, 10-15 parts of rhizoma cyperi, 10-20 parts of rhizoma corydalis, 10-15 parts of radix aucklandiae and 6-9 parts of semen strychni preparata.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the traditional Chinese medicine composition which has the advantages of simple prescription, simple preparation method, clear drug effect for treating gout, small toxic and side effects and capability of further improving the blood lipid metabolism of patients.
The purpose of the invention is realized by the following technical scheme:
the composition for treating acute gout comprises the following raw materials in parts by weight: 1-10 parts of gypsum, 1-10 parts of rhizoma anemarrhenae, 5-10 parts of lily, 1-10 parts of cassia twig, 1-5 parts of liquorice, 1-5 parts of calcined oyster and 1-10 parts of coix seed.
Preferably, the composition consists of the following components in parts by mass: 5-10 parts of gypsum, 5-10 parts of rhizoma anemarrhenae, 5-10 parts of lily, 1-5 parts of cassia twig, 1-5 parts of liquorice, 1-5 parts of calcined oyster and 1-5 parts of coix seed.
Preferably, the composition consists of the following components in parts by mass: 6 parts of gypsum, 5 parts of rhizoma anemarrhenae, 7 parts of lily, 4 parts of cassia twig, 2 parts of liquorice, 3 parts of calcined oyster and 3 parts of coix seed.
Preferably, the mass ratio of the lily to the calcined oyster is 2-5: 1.
Preferably, the mass ratio of the lily to the calcined oyster is 2-3: 1.
Preferably, the mass ratio of the total mass of the gypsum and the rhizoma anemarrhenae to the coix seed is 2-4: 1.
The efficacy of each medicine in the formula of the invention is as follows:
gypsum, gypsum, is pungent, sweet and cold in nature. Enter lung and stomach meridians. Clear heat and purge fire, astringe and promote granulation. Can be used for treating epidemic febrile disease, lung and stomach intense heat, hyperpyrexia, thirst, vexation, and surging pulse.
Zhi mu is bitter and cold. Enter lung, stomach and kidney meridians. Clear heat and purge fire, nourish kidney and moisten dryness. Can be used for treating excessive heat in lung and stomach, cough and asthma due to lung heat, and yellow and thick phlegm, such as febrile disease, hyperpyrexia with dysphoria, thirst, and surging pulse.
Lily is sweet and slightly cold. Enter heart and lung meridians. Has effects of moistening lung, relieving cough, calming heart and tranquilizing mind, and can be used for treating lung dryness or cough due to lung heat.
Gui Zhi, pungent and sweet with warm taste. Enter heart, lung and bladder meridians. Induce sweating to release exterior, warm and dredge meridians, activate yang to transform qi. Can be used for treating wind-cold exterior syndrome.
Licorice root, radix Glycyrrhizae, sweet and neutral. Enter twelve meridians. Tonify middle-jiao and Qi, purge fire and remove toxicity, moisten lung and dispel phlegm, moderate drug property, relieve spasm and alleviate pain. Can be used for treating weakness of spleen and stomach and deficiency of qi and blood.
Mu Li is salty, astringent and slightly cold. Enter liver, gallbladder and kidney meridians. Tranquilization, pacifying liver and subduing yang, astringing and inducing astringency, softening hardness and dissipating nodulation, relieving hyperacidity and alleviating pain. Can be used for treating uneasiness, palpitation, insomnia, etc. Calcined mu Li is usually used to astringe, soften hard mass and make sour.
Coix seed, semen Coicis, sweet, bland and slightly cold. It enters spleen, kidney and lung meridians. Induce diuresis and drain dampness, invigorate spleen, remove arthralgia, expel pus and cure abscess. Can be used for treating dysuresia, edema, loempe, damp-warm syndrome, etc.
It is a further object of the present invention to provide a process for preparing the above composition, comprising the steps of: decocting Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen in water, filtering, and concentrating.
Preferably, soaking for 20-40min before decocting;
preferably, the drying is vacuum drying under reduced pressure. The ratio of the volume of the added water to the total mass of the gypsum, the rhizoma anemarrhenae, the lily, the cassia twig, the honey-fried licorice root, the calcined oyster shell and the coix seed is 8-12: 1 mL/g.
Preferably, 0.05% of cosolvent is added into water during decoction according to the mass ratio of the cosolvent to the water, wherein the cosolvent is a cosolvent with the mass ratio of 3-5: 1-2: 0.1 of soybean lecithin, sucrose ester and Tween-80.
The invention also aims to provide application of the composition or the composition prepared by the preparation method in preparing a medicine for treating acute gout.
The invention has the beneficial effects that:
(1) the rhizoma anemarrhenae is bitter and cold, enters lung, stomach and kidney channels, can clear excess heat of the lung and stomach channels, and is a monarch drug; gypsum, Gypsum Fibrosum, pungent and sweet in flavor and cold in nature, enters lung and stomach meridians, and helps Zhi mu to relieve excess heat in lung and stomach meridians, while Lily bulb, sweet and slightly cold in nature. Enter heart and lung meridians. The traditional Chinese medicine composition has the effects of moistening lung, relieving cough, calming heart and soothing nerves, and the two medicines are combined as ministerial medicines; the semen coicis is sweet, bland and slightly cold, is intended to enhance the function of promoting diuresis and can invigorate the spleen and remove paralysis at the same time; prepared licorice root, radix Glycyrrhizae Praeparata, has the effects of relieving spasm and pain, and harmonizing the recipe; ramulus Cinnamomi warms and unblocks meridians and collaterals without pain; calcined oyster is salty, astringent and slightly cold, has the effects of softening hardness to dissipate stagnation, relieving hyperacidity and relieving pain, and the four medicines are used as adjuvant medicines. The medicines in the formula are organically combined and supplement each other to play the effects of clearing the internal heat of the lung and stomach and relieving the arthralgia of the channels and collaterals.
(2) The components of the invention are strictly proportioned, the preparation method is simple and easy to obtain, the prepared composition can prevent the attack of acute gout, relieve joint pain and swelling caused by ventilation, effectively reduce uric acid in blood and further improve the blood lipid metabolism of organisms, and has high safety.
Detailed Description
The invention is further illustrated by the following specific examples.
Example 1
The composition for treating acute gout comprises the following raw materials in parts by weight: 1 part of gypsum, 2 parts of rhizoma anemarrhenae, 5 parts of lily, 2 parts of cassia twig, 1 part of liquorice, 1 part of calcined oyster and 1 part of coix seed.
The preparation method of the composition comprises the following steps:
pulverizing Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen, soaking in 5 times of water for 40min, boiling with strong fire, decocting with slow fire for 20min, filtering, and concentrating to obtain decoction 1/3.
Example 2
The composition for treating acute gout comprises the following raw materials in parts by weight: 10 parts of gypsum, 8 parts of rhizoma anemarrhenae, 10 parts of lily, 10 parts of cassia twig, 5 parts of liquorice, 5 parts of calcined oyster and 9 parts of coix seed.
The preparation method of the composition comprises the following steps:
pulverizing Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen, soaking in 12 times of water for 20min, boiling with strong fire, decocting with slow fire for 40min, filtering, and concentrating to obtain decoction 1/3.
Example 3
The composition for treating acute gout comprises the following raw materials in parts by weight: 6 parts of gypsum, 5 parts of rhizoma anemarrhenae, 7 parts of lily, 4 parts of cassia twig, 2 parts of liquorice, 3 parts of calcined oyster and 3 parts of coix seed.
The preparation method of the composition comprises the following steps:
pulverizing Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen, soaking in 10 times of water for 30min, boiling with strong fire, decocting with slow fire for 30min, filtering, and concentrating to obtain decoction 1/3.
Example 4
The composition for treating acute gout comprises the following raw materials in parts by weight: 6 parts of gypsum, 5 parts of rhizoma anemarrhenae, 7 parts of lily, 4 parts of cassia twig, 2 parts of liquorice, 3 parts of calcined oyster and 3 parts of coix seed.
The preparation method of the composition comprises the following steps:
pulverizing Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen, adding 10 times of water, adding 0.05% dissolving promoter, boiling with strong fire, decocting with slow fire for 30min, filtering, and concentrating to obtain decoction 1/3. Wherein the mass ratio of the cosolvent to the solid phase is 5: 2: 0.1 of soybean lecithin, sucrose ester and tween-80.
Example 5
The composition for treating acute gout comprises the following raw materials in parts by weight: 6 parts of gypsum, 5 parts of rhizoma anemarrhenae, 7 parts of lily, 4 parts of cassia twig, 2 parts of liquorice, 3 parts of calcined oyster and 3 parts of coix seed.
The preparation method of the composition comprises the following steps:
pulverizing Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen, adding 10 times of water, adding 0.05% dissolution accelerator, boiling with strong fire, decocting with slow fire for 30min, filtering, and concentrating to obtain the decoction 1/3. Wherein the mass ratio of the cosolvent to the solid phase is 3: 1: 0.1 of soybean lecithin, sucrose ester and tween-80.
Comparative example 1
The difference between the comparative example and the example 3 is that the mixture ratio of the lily to the calcined oyster shell is different. The specific method comprises the following steps:
the composition for treating acute gout comprises the following raw materials in parts by weight: 6 parts of gypsum, 5 parts of rhizoma anemarrhenae, 5 parts of lily, 4 parts of cassia twig, 2 parts of liquorice, 5 parts of calcined oyster and 3 parts of coix seed.
The preparation method of the composition comprises the following steps:
pulverizing Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen, adding 10 times of water, boiling with strong fire, decocting with slow fire for 30min, filtering, and concentrating to obtain decoction 1/3.
Comparative example 2
The difference between the comparative example and the example 3 is that the total mass of the gypsum and the rhizoma anemarrhenae is different from the mass ratio of the coix seeds. The specific method comprises the following steps:
the composition for treating acute gout comprises the following raw materials in parts by weight: 5 parts of gypsum, 2 parts of rhizoma anemarrhenae, 7 parts of lily, 4 parts of cassia twig, 2 parts of liquorice, 3 parts of calcined oyster and 7 parts of coix seed.
The preparation method of the composition comprises the following steps:
pulverizing Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen, adding 10 times of water, boiling with strong fire, decocting with slow fire for 30min, filtering, and concentrating to obtain decoction 1/3.
Comparative example 3
The difference between the comparative example and the example 3 is that coix seed is adjusted to tuckahoe, cassia twig is adjusted to honeysuckle, licorice is adjusted to atractylodes, and the rest is the same as the example 3.
Comparative example 4
The difference between the comparative example and the example 4 is that the mass ratio of the cosolvent to the cosolvent is 1: 1: 0.1 soya lecithin, sucrose ester and tween-80, the remainder remaining in accordance with example 4.
Test example 1 therapeutic Effect of the composition of the present invention on rats with acute gouty arthritis
1.1 purpose: the therapeutic effect of the composition on rats with acute gouty arthritis is researched, and the swelling degree of ankle joints and the gait of rats are observed.
1.1 Experimental animals and groups: male SD rats, 200 ± 20g in body weight, normal grade, 12 groups, normal group, model group, positive control group, examples 1 to 5 groups, comparative examples 1 to 4 groups, 8 animals per group.
1.2 animal model establishment
Preparation of 3% Potassium Oxonate: weighing 3g of oteracil potassium, and dissolving with 97mL of normal saline to obtain the product;
preparation of sodium urate solution: 1250mg of sodium urate crystal are weighed and dissolved by 45mL of physiological saline and 5mL of Tween-80 to obtain the sodium urate crystal.
Intraperitoneal injection is carried out 2 times a day for 2 weeks by using 1mL/100g of 3% oteracil potassium solution.
1.3 Experimental methods
Injecting normal group rat abdominal cavity with normal saline, molding the rest groups by using the method of establishing 1.2 animal model of each group rat, and after molding for one week, intragastrically administering colchicine 0.65mg/kg to the positive control group once a day; the concentrated solution (30 g/kg of crude drug amount, and the concentrated solution is continuously concentrated to 4mL before gastric lavage) prepared by the corresponding group of the groups of examples 1-5 and comparative examples 1-4 is administered by gastric lavage, and the model group and the control group are administered with normal saline with the same quality. The administration method comprises the following steps of performing intragastric administration once a day for 3 consecutive days, inserting 45-degree injection needle of No. 6 into the inner side of a tibial tendon on the back side of the right rear ankle joint of each group of rats except a normal group before performing intragastric administration on the 4 th day, enabling a needle head to be abutted against periosteum, injecting 0.2mL of 25mg/mL sodium urate solution into the ankle joint cavity of the rats, continuing administration for 2 days, measuring the thickness of the joint before performing intragastric bypass administration and after performing last administration on the right rear ankle joint of the rats by using a spiral micrometer, observing gait changes of the rats before and after administration, and taking blood by an anesthesia eyeball to measure the content of uric acid, triglyceride and total cholesterol in the serum of each group of rats. The grading standard of the gait behaviors of the rats is as follows:
level 0: normal walking, marking 0 point;
stage I: slight lameness, slight bending of the lower limb to be tested, marked 1 point;
and II, stage: moderate lameness, the tested lower limb just touches the ground, and 2 points are marked;
grade III: severe lameness, the lower limb leaving the ground, three feet landing and walking, mark 3 points.
1.4 statistics and analysis
SPSS13.0 statistical software is adopted for data processing, variance analysis and LSD-t test are adopted for comparison among groups, and P <0.05 is the difference and has statistical significance. The results are shown in tables 1 and 2.
TABLE 1 therapeutic Effect of the compositions on arthritis in rats
TABLE 2 hypouricemic and hypolipidemic actions of the compositions
| Grouping | Blood uric acid (mu mol/L) | Triglyceride (mmol/L) | Total cholesterol (mmol/L) |
| Normal group | 135.74±24.13a | 1.59±0.16a | 2.10±0.27a |
| Model set | 286.35±15.21b | 1.65±0.21a | 2.16±0.45a |
| Positive group | 269.78±14.95b | 1.62±0.42a | 2.14±0.32a |
| Example 1 | 158.73±26.83c | 1.50±0.13b | 2.01±0.62b |
| Example 2 | 158.25±21.68c | 1.51±0.36b | 2.00±0.48b |
| Example 3 | 157.68±13.59c | 1.50±0.18b | 1.98±0.27b |
| Example 4 | 141.47±17.28e | 1.38±0.30c | 1.87±0.43c |
| Example 5 | 139.75±13.58e | 1.39±0.81c | 1.85±0.37c |
| Comparative example 1 | 168.72±25.16d | 1.54±0.14b | 2.06±0.19b |
| Comparative example 2 | 175.28±12.83d | 1.49±0.13b | 1.97±0.24b |
| Comparative example 3 | 192.58±16.74d | 1.61±0.27a | 2.12±0.41a |
| Comparative example 4 | 152.73±15.26c | 1.46±0.18b | 1.95±0.52b |
Note: different letters in the same column represent a statistical difference between groups, P < 0.05.
The composition can effectively prevent acute gout and alleviate symptoms of acute gout by clearing lung-heat and stomach excess heat, relieving arthralgia of channels and collaterals, reducing blood uric acid through multi-target effect of traditional Chinese medicines and integral regulation of traditional Chinese medicine. Can replace colchicine to be used for treating acute gout to a certain extent, can reduce the side effect of western medicine treatment to the maximum extent, and has wide market prospect.
The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.
Claims (10)
1. The composition for treating acute gout is characterized by comprising the following raw materials in parts by mass: 1-10 parts of gypsum, 1-10 parts of rhizoma anemarrhenae, 5-10 parts of lily, 1-10 parts of cassia twig, 1-5 parts of liquorice, 1-5 parts of calcined oyster and 1-10 parts of coix seed.
2. The composition according to claim 1, wherein the composition consists of the following components in parts by mass: 5-10 parts of gypsum, 5-10 parts of rhizoma anemarrhenae, 5-10 parts of lily, 1-5 parts of cassia twig, 1-5 parts of liquorice, 1-5 parts of calcined oyster and 1-5 parts of coix seed.
3. The composition according to claim 1, wherein the composition consists of the following components in parts by mass: 6 parts of gypsum, 5 parts of rhizoma anemarrhenae, 7 parts of lily, 4 parts of cassia twig, 2 parts of liquorice, 3 parts of calcined oyster and 3 parts of coix seed.
4. The composition of claim 1, wherein the mass ratio of the lily to the calcined oyster shell is 2-5: 1.
5. The composition according to claim 1, wherein the mass ratio of the lily to the calcined oyster is 2-3: 1.
6. The composition of claim 1, wherein the mass ratio of the total mass of the gypsum and the rhizoma anemarrhenae to the coix seed is 2-4: 1.
7. A process for preparing a composition according to any one of claims 1 to 5, comprising the steps of: decocting Gypsum Fibrosum, rhizoma anemarrhenae, Bulbus Lilii, ramulus Cinnamomi, radix Glycyrrhizae Preparata, Concha Ostreae preparata and Coicis semen with water to obtain decoction, filtering, and concentrating to 1/3 of the decoction; or concentrating the decoction, drying under reduced pressure, and making into oral preparation, preferably granule.
8. The preparation method according to claim 6, wherein the soaking is performed for 20-40min before the decoction; the drying is vacuum drying under reduced pressure; the ratio of the volume of the added water to the total mass of the gypsum, the rhizoma anemarrhenae, the lily, the cassia twig, the honey-fried licorice root, the calcined oyster shell and the coix seed is 8-12: 1 mL/g.
9. The preparation method according to claim 6, wherein 0.05% of cosolvent is added into water during the decoction according to the mass of the water, and the cosolvent is a mixture of the cosolvent and the cosolvent in a mass ratio of 3-5: 1-2: 0.1 of soybean lecithin, sucrose ester and Tween-80.
10. Use of a composition according to any one of claims 1 to 6 or a composition prepared by a method according to any one of claims 7 to 9 in the manufacture of a medicament for the treatment of acute gout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110716052.9A CN114588233B (en) | 2021-06-25 | 2021-06-25 | Composition for treating acute gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110716052.9A CN114588233B (en) | 2021-06-25 | 2021-06-25 | Composition for treating acute gout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114588233A true CN114588233A (en) | 2022-06-07 |
| CN114588233B CN114588233B (en) | 2023-01-03 |
Family
ID=81803926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110716052.9A Active CN114588233B (en) | 2021-06-25 | 2021-06-25 | Composition for treating acute gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114588233B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105194460A (en) * | 2015-10-22 | 2015-12-30 | 刘凯 | Traditional Chinese medicine preparation for treating acute episode stage of wind-damp-heat type gout |
| CN107715014A (en) * | 2017-10-31 | 2018-02-23 | 南宁市共健源健康科技有限公司 | A kind of Chinese medicine composition for gout and preparation method thereof |
| CN107929598A (en) * | 2017-12-04 | 2018-04-20 | 代立新 | A kind of Chinese medicine composition for treating gout and preparation method thereof |
-
2021
- 2021-06-25 CN CN202110716052.9A patent/CN114588233B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105194460A (en) * | 2015-10-22 | 2015-12-30 | 刘凯 | Traditional Chinese medicine preparation for treating acute episode stage of wind-damp-heat type gout |
| CN107715014A (en) * | 2017-10-31 | 2018-02-23 | 南宁市共健源健康科技有限公司 | A kind of Chinese medicine composition for gout and preparation method thereof |
| CN107929598A (en) * | 2017-12-04 | 2018-04-20 | 代立新 | A kind of Chinese medicine composition for treating gout and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 贾建云等: "中医药治疗痛风用药规律分析", 《四川中医》 * |
| 邱复亮: "白虎加桂枝汤合四妙散治疗风湿郁热型急性痛风性关节炎30例", 《浙江中医杂志》 * |
| 陈玉婷: "近年中医治疗急性痛风性关节炎述要", 《河南中医》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114588233B (en) | 2023-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102552580B (en) | Formula of orally-taken drug for treating lithangiuria and difficult urination and preparation technology of drug | |
| CN101284114A (en) | Medicine for treating rheumatism and rheumatoid disease | |
| CN102805817B (en) | Medicine for treating rheumatism and rheumatoid diseases | |
| CN104258278A (en) | Gushangling (for bone injury) spray | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN103611021B (en) | Be used for the treatment of medicine of Vesica sus domestica inflammation and preparation method thereof | |
| CN114588233B (en) | Composition for treating acute gout | |
| CN104547489A (en) | Use of traditional Chinese medicine composition in preparation of medicine for treating comminuted fracture | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN104800443A (en) | Bone setting agent with functions of tonifying kidney and regenerating bone marrow | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN103656277B (en) | The medicine for the treatment of hepatic ascites | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN101480456B (en) | Pharmaceutical composition for treating rheumatism and heumatism and preparation method thereof | |
| CN1994415B (en) | Orally administered Chinese medicine for treating dysmenorrhea | |
| CN105943700A (en) | Traditional Chinese medicine composition capable of tonifying kidney and relieving paralysis and preparation method and application thereof | |
| CN105079487A (en) | Traditional Chinese medicine composition for treating heat stranguria | |
| CN117717594A (en) | Traditional Chinese medicine composition for treating lumbar muscle degeneration as well as preparation method and application thereof | |
| CN104758888A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| CN104758889A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN104547865A (en) | Application of traditional Chinese medicine preparation in preparing medicine for treating senile dementia | |
| CN114984155A (en) | Traditional Chinese medicine formula for treating apoplexy and preparation process thereof | |
| CN104127709A (en) | Traditional Chinese medicinal composition for curing chronic renal insufficiency | |
| CN116920064A (en) | Traditional Chinese medicine formula for treating rheumatic bone diseases and processing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 100005 room g121-122, building B, COFCO Plaza, Dongcheng District, Beijing Applicant after: Beijing jingyihesheng Pharmaceutical Technology Co.,Ltd. Address before: 100005 room g121-122, building B, COFCO Plaza, Dongcheng District, Beijing Applicant before: Beijing Jingyi Hesheng Mayo TCM clinic Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |